(Q39785574)

14 September 2017

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor (English)

1 reference

14 September 2017

Joey L Methot

1

1 reference

14 September 2017

Dawn Mampreian Hoffman

2

1 reference

14 September 2017

David J Witter

3

1 reference

14 September 2017

Matthew G Stanton

4

1 reference

14 September 2017

Paul Harrington

5

1 reference

14 September 2017

Christopher Hamblett

6

1 reference

14 September 2017

Phieng Siliphaivanh

7

1 reference

14 September 2017

Kevin Wilson

8

1 reference

14 September 2017

Jed Hubbs

9

1 reference

14 September 2017

Richard Heidebrecht

10

1 reference

14 September 2017

Astrid M Kral

11

1 reference

14 September 2017

Nicole Ozerova

12

1 reference

14 September 2017

Judith C Fleming

13

1 reference

14 September 2017

Hongmei Wang

14

1 reference

14 September 2017

Alexander A Szewczak

15

1 reference

14 September 2017

Richard E Middleton

16

1 reference

14 September 2017

Bethany Hughes

17

1 reference

14 September 2017

Jonathan C Cruz

18

1 reference

14 September 2017

Brian B Haines

19

1 reference

14 September 2017

Melissa Chenard

20

1 reference

14 September 2017

Candia M Kenific

21

1 reference

14 September 2017

Andreas Harsch

22

1 reference

14 September 2017

J Paul Secrist

23

1 reference

14 September 2017

Thomas A Miller

24

1 reference

14 September 2017

language of work or name

1 reference

2 January 2014

1 reference

ACS Medicinal Chemistry Letters

14 September 2017

1 reference

14 September 2017

5

1 reference

14 September 2017

4

1 reference

14 September 2017

340-345

1 reference

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

The structure and function of histone deacetylases: the target for anti-cancer therapy.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Isoform-selective histone deacetylase inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Histone deacetylase inhibitors: from bench to clinic

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Sin meets NuRD and other tails of repression.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Histone Deacetylase Inhibitors

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027730

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24900838

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1021/ML4004233

1 reference

14 September 2017

1 reference

14 September 2017

PubMed publication ID

24900838

1 reference